Loading…
CNS Pharmaceuticals, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CNSP.
▼ -100.0% over 5Y.
today you would have $0.00▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.25 | $72.00 | $38,100.00 | $72,000.00 | |
| P/B | 0.7x | 0.7x | 1.4x | — | 0.5x |
| EPS | -$35.75 | -$466.89 | -$91,068.72 | -$288,191.21 | |
| ROE | -240.55% | -350.48% | -240.55% | — | -187.81% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CUPRCuprina Holdings (Cayman) LTD | $3.01 | — | 2.0x | — | -1569.06% | $8.07M |
| ALZNAlzamend Neuro, Inc. | $1.66 | — | 9.7x | — | -373.18% | $8.01M |
| AIDX20/20 Biolabs, Inc. | $0.62 | — | 4.7x | — | -331.22% | $7.97M |
| LUCYInnovative Eyewear Inc | $0.95 |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Company description provided by Yahoo Finance.
| — |
| 0.9x |
| — |
| -84.58% |
| $8.18M |
| SNGXSoligenix Inc | $0.38 | — | 1.2x | — | -241.65% | $8.2M |
| BMGLBasel Medical Group Ltd | $5.24 | — | 1.7x | — | -147.37% | $8.2M |